SCYNEXIS INC (SCYX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US8112922005
SCYNEXIS INC financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 20.60 m USD |
| Operating income | -16.07 m USD |
| EBIT | -8.44 m USD |
| Net income | -8.61 m USD |
| Diluted EPS – continuing operations | -0.17 USD |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About SCYNEXIS INC
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
More stocks
- Cohen & Co Inc. (COHN)
- LeonaBio, Inc. (LONA)
- RESERVE PETROLEUM CO (RSRV)
- TuSimple Holdings Inc. (TSPH)
- DMS Propertindo Tbk PT (KOTA.JK)
- Inmune Bio, Inc. (INMB)
- Laser Photonics Corp (LASE)
- VNUE, Inc. (RDCT)
- PFS Bancorp, Inc. (PFSB)
- Brand Engagement Network Inc. (BNAI)
- OneMedNet Corp (ONMD)
- Atari SA (ALATA.PA)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.